TagsOncology 
TARGRETIN™

TARGRETIN™ (bexarotene) MAIN LIFE HK Reg. No. HK-68294 (04 Jul, 2024) Composition: 1 Targretin™ (bexarotene) is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). Targretin™ is available in c...

Aug 20, 2024
EXKIVITY

EXKIVITY (mobocertinib) TAKEDA Indications: EXKIVITY is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, ...

Feb 6, 2024
COLUMVI

COLUMVI (glofitamab-gxbm) ROCHE Indications: COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from foll...

Feb 6, 2024
Trodelvy

Trodelvy (sacituzumab govitecan) Gilead Presentation: Each vial contains 180 mg of Sacituzumab govitecan. Off-white to yellowish lyophilized powder in a single-dose vial. Indications: Trodelvy is indicated for the treatment of adult patients wit...

Dec 18, 2023
Exkivity

Exkivity® ( mobocertinib ) 1-3 Takeda Mobocertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that selectively inhibits and irreversibly binds to EGFR exon 20 insertion mutations at lower concentrations than Wild type (...

Jun 13, 2023